CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Gemcitabine, Carboplatin, Bevacizumabdrug
Likely dose
Gemcitabine, Carboplatin, Bevacizumab 2000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00400803
NCT00400803Phase 2Completed
CompareCT.gov

Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC

Masonic Cancer Center, University of Minnesota·interventional·Posted Nov 17, 2006·Updated Dec 28, 2017

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, Carboplatin, Bevacizumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 38 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsEli Lilly and Company, Genentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 17, 2006
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.6 years ago

Interventions

Gemcitabine, Carboplatin, Bevacizumabdrug

Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.